Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
  • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
  • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
  • C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D277/34—Oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D277/36—Sulfur atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

• the present invention involves novel di-and tri- substituted thiazoles having pharmaceutical activity as ⁇ -adrenergic blocking agent.
• Thiazoles having an aminohydroxypropoxy substituent in the 2-position with or without a specific additional substituent in the 4 or 5- position are known and are taught to have ⁇ -adrenergic stimulating activity (U.S. 3,850,945).
• Thiazoles having an aminohydroxypropoxy substituent in the 4 or 5-position with no additional substitution are also known and are taught to have ⁇ -adrenergic stimulating activity (U.S. 3,850,947, U.S. 3,850,946).
• Thiazoles having the aminohydroxypropoxy substituent in the 2-position with an aminocarbonyl, formamido, substituted oxycarbonyl amino group in the 4 or 5-position are known and taught to have S-adrenergic blocking activity (U.S.3,897,411).
• Thiazoles having the following formula are known and are taught to be ⁇ -adrenergic blocking agents. (U.S. 3,897,442). Thiazoles of the formula are known and are taught to block ⁇ -adrenergic receptors (U.S. 3,932,400).
• thiazoles having a 4(3-amino-2-OR-propoxy) substituent have been discovered.
• the thiazoles are active as ⁇ -adrenergic blocking agents.
• An embodiment of the present invention is compounds having the formula and pharmaceutically acceptable salts thereof wherein
• the pharmaceutically acceptable salts are the acid addition salts of the formula I free base.
• Suitable acids include organic as well as inorganic acids.
• useful organic acids are carboxylic acids such as acetic acid, pamoic acid, maleic acid, succinic acid, citric acid, tartaric acid, oxalic acid, malic acid, pivalic acid, heptanoic acid, lauric acid, propanoic acid, pelargonic acid, oleic acid and the like, and non-carboxylic acids such as isethionic acid.
• useful inorganic acids are the hydrogen halides i.e., HC1, HBr, HI, phosphoric acid, sulfuric acid, and the like.
• the hydrohalide salts especially the hydro- cylorides and maleic acids, especially the hydrogen maleate, are preferred.
• R may be hydrogen or C 2 -C 12 acyl.
• the C 2 -C 12 acyl groups include alkanoyl groups such as acetyl, pivaloyl, dodecanoyl, hexanoyl, succinoyl and the like - and carbocyclic aroyl groups such as benzoyl, 1- or 2- naphthoyl, p-methylbenzoyl, p-phenylbenzoyl and the like.
• the C 2 -C 6 alkanoyl and benzoyl groups are preferred acyl groups. Hydrogen is a most.prdferred R group.
• the R 1 substituent includes C 1 -C 12 alkyl, groups and preferably the C l -C 6 alkyl groups.
• the alkyl groups are exemplified by methyl, C 12 H 25 , hexyl, 2-ethylhexyl, isopropyl, sec-butyl, heptyl and the like.
• the C 3-4 branched chain alkyl R 1 groups are more preferred, with t-butyl being a most preferred group.
• R 2 includes H, CF 3 , C 6 -C 12 carbocyclic aryl such as phenyl, monosubstituted phenyl e.g. p-tolyl, o-halophenyl, p-nitrophenyl, p-methoxyphenyl and p-halophenyl; indanyl; 1- or 2-naphthyl and the like, 6-membered-N-heteroaryl such as 2-, 3- or 4-pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl and the like; thienyl, furfuryl, C 1 -C 6 alkyl, e.g.
• R 2 groups are hydrogen, C 1 -C 6 alkyl and C 1 -C 6 alkylthio, especially CH 3 -S.
• the R 3 substituent includes CF 3 , C 1 -C 6 alkyl, CN, C 6 -C 1 2 carbocyclic aryl such as phenyl, carboxylic acid esters and amides.
• the C 1 -C 6 alkyl group is exemplified by CH 3 , isopropyl, and the like.
• the ester is C 1 -C 6 alkylester exemplified by -COOCH 3 , -COOC 6 H 13 , -COOCH(CH 3 ) 2 , -COOC 2 H 5 and the like and C 6 -C 12 arylester, preferably carbocyclic aryl, exemplified by C 6 H 5 -OOC, p-CH 3 -C 6 H 4 -OOC-, p-C 6 H 5 -C 6 H 4 -OOC-, C 9 H 9 -OOC- and the like.
• the amide group includes -CONH 2 , C l -C 6 substituted amide groups such as -CON(CH 3 ) 2 , -CON(C 6 H 13 ) 2 , -CONHC 2 H 5 , -CON (sec. butyl) 2 and the like and carbonyl heterocyclic groups such as of the R 3 groups, CN, CF 3 and amide, especially CONH 2 , are preferred.
• the formula I compounds have a chiral center (at the 2 carbon in the propoxy substituent) which confers optical activity.
• the optical isomers are designated conventionally as L and D, 1 and d, + and -, S and R or by combinations of these symbols. Where the formula or compound name herein carries no specific designation, the formula or name includes the individuvl isomers, the mixtures thereof and racemates.
• the thiazole compounds which are preferred have the formula Formula II compounds where R 2 is H, C 1 -C 6 alkylthio, preferably CH 3 -S-, or said heteroaryl groups, especially pyridyl, R 3 is CN, CF 3 , amide, C 1 -C 6 alkyl or said ester group and R 1 is C l -C 6 alkyl especially C 3 -C 4 branched alkyl are more preferred.
• R 2 is said alkylthio or heteroaryl
• R 3 is CN, CF 3 , CONH 2 , C l -C 6 alkyl or said ester
• R 1 is C 3 -C 4 branched alkyl.
• Another preferred group of thiazoles has the formula where R 2 is H, C 1 -C 6 alkyl, C 1 -C 6 alkylthio or pyridyl, R 3 is CN, CF 3 , C l -C 6 alkyl or CONH.
• said branched alkyl is tert.-butyl
• R 2 is H, CH 3 , CH 3 S or pyridyl
• R 3 is CN, CH 3 , CONH 2 or CF 3
• the thiazoles where said branched alkyl is tert.-butyl, R 2 is H, CH 3 S or pyridyl and R 3 is CN or CONH 2 are partic- cularly preferred.
• optical isomers those having the S-isomer configuration are preferred.
• the thiazoles of the present invention have ⁇ -adrenergic blocking activity. This was determined in an in-vivo test using dogs as the test animals. In this test, representative thiazole compounds, were found to counteract the a-adrenergic stimulating effect of isoproterenol.
• Certain of the present thiazoles also exhibit an antihypertensive effect of immediate onset when administered to a spontaneously hypertensive (SH) rat.
• SH spontaneously hypertensive
• the present thiazoles also show random vasodilator activity.
• the present thiazole compounds will effect ⁇ -adrenergic blockade in humans.
• This ⁇ -adrenergic blocking effect is useful in the therapeutic treatment of various cardiovascular conditions such as angina pectoris, arrhythmia etc.
• the daily dosage may range from about 1.5 mg. to about 3000 mg.
• Preferred daily dosages are about 6.5 mg. to about 200 mg.
• Conventional dosage forms suitable for oral as well as parenteral, e.g. intravenous, intraperitoneal etc., administration are used.
• Oral dosage forms include tablets, capsules, troches, liquid formulations e.g. solutions, emulsions, elixirs, etc.
• parenteral dosage forms include liquid formulations especially solutions.
• the compositions are prepared using conventional procedures and compounding ingredients such as starch, sterile water, flavoring additivies, antioxidants, binders, vegetable oils, sweetening agents, glycerine and the like.
• Thiazoles which exhibit the immediate onset antihypertensive activity are useful for treating hypertensive humans at daily dosages ranging from about 100 to about 3000 mg. administered in oral or parenteral dosage forms.
• the present thiazoles can be prepared by any convenient process.
• Z is an alkyl or arylsulfonyl group.
• sulfonyl groups are CH 3 -SO 2 -, C 6 H 5 -SO 2 -, NO 2 -C 6 H 4 SO 2 -, p-CH 3 -C 6 H 4 -SO 2 -, mesitylene-SO 2 -, CH 3 O-C 6 H 4 -SO 2 -, trichlorobenzene-SO 2 -, C 16 H 33 -SO 2 - and the like.
• Suitable bases are alkali metal bases such as K 2 CO 3 , K-O-C(CH 3 ) 3 , NaH, organolithiums e.g. phenyllithium, n-butyllithium, lithium diisopropyl amide and the like.
• R 6 is hydrogen or other C 1 -C 12 alkyl or C 6 -C 12 carbocyclic aryl residue of any suitable v aldehyde
• suitable aldehydes are the aryl aldehydes such as benzaldehyde, naphthaldehyde 4-phenylbenzaldehyde, furfural, bromobenzaldehyde, tolualdehyde, mesitaldehyde and the like, or an alkanal such as acetaldehyde, butyraldehyde, and the like.
• the process for preparing oxazolidines where Z is hydrogen (and a related coupling reaction) is disclosed in U.S. 3,718,647 and U.S. 3,657,237 and to the extent necessary the pertinent disclosure is incorporated herein by reference.
• the coupling reaction can be carried out at temperatures ranging from about 0°C. to about 130°C. A temperature range of about 50°C. to about 130°C is preferred.
• the reaction is generally carried out in a solvent. Any suitable solvent may be used. Examples of useful solvents are dimethylformamide, dimethylsulfoxide, hexamethylphosphoramide, tert. butanol, dioxane, toluene, acetone and the like.
• the hydrolysis is carried out using a conventional acid system e.g. by treatment with a solution of any suitable acid such as HC1, H 2 S0 4 , CH 3 COOH and the like.
• the hydrolysis product can be directly obtained as the salt of the acid used for the hydrolysis. Ordinarily, the product IA is recovered as the free base after conventional neutralization of the salt.
• the coupling reaction is ordinarily carried out at atmospheric pressure. Higher pressures may be used if desired.
• racemic oxazolidine (formula V)
• the product is obtained as a racemate.
• the racemate may be separated into its individual enantiomers by conventional resolution techniques.
• R 6 in the oxazolidine (e.g. formula V or VI) is other than hydrogen, in addition to the chiral center at oxazolidine position 5 there is a second chiral center at position 2.
• R 6 in the oxazolidine e.g. formula V or VI
• this designation refers only to the optical configuration around the carbon atom at the 5 position.
• the thiazole product (IA) may be obtained directly as a single enantiomer. This provides a convenient way for directly preparing individual isomers of the present thiazoles.
• Thiazoles represented by formula I wherein R is other than hydrogen are conveniently prepared by treating the corresponding thiazole where R is hydrogen with an appropriate acylating agent such as an acyl halide, e.g. undecanoyl chloride, pivaloyl chloride, benzoylchloride, p-methoxybenzoyl chloride, an anhydride e.g. acetic anhydride and the like.
• an acylating agent such as an acyl halide, e.g. undecanoyl chloride, pivaloyl chloride, benzoylchloride, p-methoxybenzoyl chloride, an anhydride e.g. acetic anhydride and the like.
• the compounds of the present invention also include the pharmaceutically acceptable salts of the novel thiazoles. These salts are conveniently prepared e.g. by treating the thiazole with an appropriate amount of a useful acid, generally in a suitable solvent.
• the thiazoles having an alkylsulfinyl or alkylsulfonyl substituent are prepared by oxidizing the corresponding C 1 -C 6 alkylthio containing compound. Any suitable oxidizing agent, e.g. H 2 0 2 , may be used. The following equation illustrates the reaction
• the solution is cooled to 0-10°C., poured into H 2 0 (100 ml.) and extracted with ether (3 x 100 ml.).
• the organic layer is extracted with IN HC1 (2 x 50 ml.) and the acid layer added to NaOAc (8.2 g., 0.1 m).
• the solution is extracted with ether (2 x 50 ml.).
• the aqueous layer is neutralized with saturated Na 2 C0 3 and extracted with CHCl3 (3 x 100 ml.).
• the organic layer is dried over Na 2 SO 4 , filtered and concentrated to dryness.
• the residue is chromatographed on alumina (activity grade II, E.
• ethyl-4-hydroxy-2-methylthiazole-5-carboxylate (20 g., 0.091 m), DMF (200 ml.) and NaH (50% mineral oil, 5.0 g., 0.104 m).
• a solution of the tosylate of (S)-2-phenyl-3-tert.butylamino-5-hydroxymethyloxazolidine (0.106 m) in DMF (150 ml.) is added at room temperature and the solution heated on a steam bath with stirring. After 15 hours, the solution is cooled to 0-10°C., poured into H 2 0 (1 1.) and extracted with ether (3 x 300 ml.).
• Example 2A Using the procedure of Example 2A, ethyl 4-hydroxy-2-methylthiazole-5-carboxylate (9.35 g., 0.05 m), DM F (100 ml.), NaH (57% mineral oil, 2.5 g., 0.052 m) and the tosylate of 2-phenyl-3-tert.butyl- amino-2-hydroxymethyloxazolidine (0.053 m) in DMF (100 ml.) are reacted to yield 4.7 g. (30%) of ethyl 2-methyl-4-(3-tert.butylamino-2-hydroxypropoxy)thiazole-5-carboxylate.
• Example 2A Using the procedure of Example 2A, ethyl 4-hydroxy-2-methylthiazole-5-carboxylate (28 g., 0.15 m), DMF (500 ml.), NaH (50% mineral oil, 7.5 g., 0.16 m) and the tosylate of (S) 2-phenyl-3-tert.-butylamino-5-hydroxymethyloxazolidine (0.15 m) in DMF (100 ml.) are reacted to yield 9.8 g. (20%) of (S) ethyl 2-methyl-4-(3-tert. butylamino-2-hydroxypropoxy)thiazole-5-carboxylate.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Neurosurgery (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Thiazole And Isothizaole Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (3)

Publications (2)

Family

ID=27122448

Family Applications (1)

Country Status (3)

Cited By (1)

Families Citing this family (6)

Citations (2)

Family Cites Families (2)

• 1978
  • 1978-04-17 US US05/897,075 patent/US4260609A/en not_active Expired - Lifetime
  • 1978-06-01 EP EP78100053A patent/EP0000032B1/fr not_active Expired
  • 1978-06-01 JP JP6501878A patent/JPS543063A/ja active Granted

Patent Citations (2)

Also Published As

Similar Documents

Legal Events